These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23942072)

  • 1. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
    MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
    Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
    Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
    Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
    Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
    Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
    Roudgari H; Miedzybrodzka ZH; Haites NE
    Fam Cancer; 2008; 7(3):199-212. PubMed ID: 18097771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
    Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
    J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
    Lee AJ; Cunningham AP; Kuchenbaecker KB; Mavaddat N; Easton DF; Antoniou AC; ;
    Br J Cancer; 2014 Jan; 110(2):535-45. PubMed ID: 24346285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
    Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
    Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the BOADICEA model in a prospective cohort of
    Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
    J Med Genet; 2024 Jul; 61(8):803-809. PubMed ID: 38834293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
    Ghoncheh M; Ziaee F; Karami M; Poorolajal J
    Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of Risk Prediction Models for Breast Cancer and
    Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
    Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
    Thirthagiri E; Lee SY; Kang P; Lee DS; Toh GT; Selamat S; Yoon SY; Taib NA; Thong MK; Yip CH; Teo SH
    Breast Cancer Res; 2008; 10(4):R59. PubMed ID: 18627636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
    Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; ; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB
    Int J Cancer; 2019 Jul; 145(2):370-379. PubMed ID: 30725480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.